Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome

Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2016-01, Vol.2016 (2016), p.1-5
Main Authors: Ozkinay, Ferda, Kazandi, Mert, Akercan, Fuat, Sagol, Sermet, Gunduz, Cumhur, Cogulu, Ozgur, Ergenoglu, Ahmet Mete, Yeniel, Ahmet Ozgur, Buke, Baris, Guler, Ahmet, Durmaz, Burak, Aykut, Ayca, Karaca, Emin, Erturk, Biray, Ozeren, Mehmet
Format: Article
Language:English
Subjects:
Adult
Biomarkers
Biomedical research
Chromosomes
Chromosomes, Human, Pair 21 - genetics
Down syndrome
Down Syndrome - diagnosis
Down Syndrome - genetics
Down Syndrome - pathology
Female
Fetus
Fetuses
Gestational Age
Gynecology
Humans
Immunology
Karyotype
Maternal Age
Medical research
Medical screening
Medicine
Medicine, Experimental
Methods
MicroRNA
MicroRNAs
MicroRNAs - biosynthesis
MicroRNAs - genetics
Obstetrics
Plasma
Pregnancy
Pregnant women
Prenatal Diagnosis
Sample size
Studies
Ultrasonography, Prenatal
University faculty
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies.
ISSN:2314-6133
2314-6141
DOI:10.1155/2016/5312674